Inhibrx Biosciences (INBX) said late Tuesday that Brendan Eckelman, its co-founder and chief scientific officer, will leave the company to form a private biotechnology firm that signed an exclusive license agreement with Inhibrx.
The deal is for the rights to certain technologies no longer being pursued by Inhibrx. The pact includes an upfront payment upon completion of the initial funding of Eckelman's new company and other future development milestones.
Carlos Bais, Inhibrx's executive vice president of translational sciences, will be appointed chief scientific officer and David Matly will become president, in addition to his existing role as chief commercial and business development officer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.